A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

Stopped Since the availability of vaccines, a drastic drop in number of patients with increased PAP was observed and when the WHO re-categorized the COVID-19 pandemic from PHEIC to an "established and ongoing health issue" the study was withdrawn.

Conditions

• Pulmonary Hypertension
• COVID-19

Interventions

• DRUG: Sodium chloride (placebo)
• DRUG: PDNO

Sponsor

Attgeno AB

Collaborators

• [object Object]